Year: 2026
Type: article
Abstract: INDICATIONS Atopic dermatitisRecent approvals for atopic dermatitis reflect diverse mechanisms targeting itch, inflammation, and barrier dysfunction as summarized below.• Tralokinumab is an anti-interleukin (IL)-13 monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis in adults in 2021, and later expanded to include children aged 12 years and older in 2023.[1] • Abrocitinib is a selective Janus Kinase 1 (JAK-1) inhibitor originally approved for the treatment of moderate-to-severe atopic dermatitis in adults in 2022, and has now been expanded to include children older than 12 years of age.[2] • Nemolizumab, an IL-31 receptor antibody, is approved for use in moderate-to-severe atopic dermatitis in children over 12 years of age.[3] • Lebrikizumab, an IL-13 inhibitor, is approved for the treatment of moderate-to-severe atopic dermatitis in adolescents and adults.[4] • Tapinarof, a topical aryl hydrocarbon receptor (AhR) agonist, enhances barrier proteins and reduces inflammation, approved for children over 2 years of age.[5] • Roflumilast, a topical phosphodiesterase-4 (PDE-4) inhibitor, is approved for use in individuals aged 6 years and older.[6] Psoriasis and psoriatic arthritis• Tapinarof, a novel topical AhR agonist, was originally approved as 1% topical cream once daily for the treatment of mild, moderate, and severe plaque psoriasis in adults.[7] • Deucravacitinib, an oral tyrosine kinase inhibitor (TYK-2) was approved for the treatment of moderate-to-severe plaque psoriasis in 2022.[8] www.cosmoderma.org CosmoDermaSivakumar: Newly approved drugs in dermatology
Source: Cosmoderma
Author: Aravind Sivakumar
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7124749793